212 related articles for article (PubMed ID: 10888269)
21. Immunotherapy of multiple myeloma: the start of a long and tortuous journey.
Harrison SJ; Cook G; Nibbs RJ; Prince HM
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1769-85. PubMed ID: 17181491
[TBL] [Abstract][Full Text] [Related]
22. Histamine and cytokine therapy.
Hellstrand K; Hermodsson S; Naredi P; Mellqvist UH; Brune M
Acta Oncol; 1998; 37(4):347-53. PubMed ID: 9743456
[TBL] [Abstract][Full Text] [Related]
23. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets.
Mortier E; Advincula R; Kim L; Chmura S; Barrera J; Reizis B; Malynn BA; Ma A
Immunity; 2009 Nov; 31(5):811-22. PubMed ID: 19913445
[TBL] [Abstract][Full Text] [Related]
24. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
25. Histamine dihydrochloride and cancer.
Hamill FA
Integr Cancer Ther; 2003 Mar; 2(1):91-3. PubMed ID: 12941175
[No Abstract] [Full Text] [Related]
26. [New insights into cytotoxic effector cells].
Rey J; Olive D; Sébahoun G; O'Callaghan T; Costello RT
Bull Cancer; 2005 Nov; 92(11):935-43. PubMed ID: 16316827
[TBL] [Abstract][Full Text] [Related]
27. Invariant natural killer T cells and immunotherapy of cancer.
Molling JW; Moreno M; van der Vliet HJ; van den Eertwegh AJ; Scheper RJ; von Blomberg BM; Bontkes HJ
Clin Immunol; 2008 Nov; 129(2):182-94. PubMed ID: 18783990
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapeutic strategies employing RNA interference technology for the control of cancers.
Mao CP; Hung CF; Wu TC
J Biomed Sci; 2007 Jan; 14(1):15-29. PubMed ID: 17103251
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for the prevention and treatment of type 1 diabetes.
Goudy KS; Tisch R
Int Rev Immunol; 2005; 24(5-6):307-26. PubMed ID: 16318984
[TBL] [Abstract][Full Text] [Related]
30. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
32. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?
Apte RN; Voronov E
Immunol Rev; 2008 Apr; 222():222-41. PubMed ID: 18364005
[TBL] [Abstract][Full Text] [Related]
33. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
34. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
35. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
37. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
39. Regulatory T cells and asthma.
Robinson DS
Clin Exp Allergy; 2009 Sep; 39(9):1314-23. PubMed ID: 19538496
[TBL] [Abstract][Full Text] [Related]
40. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]